Clarinol CLA claims hold up
This article was originally published in The Tan Sheet
Executive Summary
Claims featured in print ads and on packaging for dietary supplement Clarinol CLA have been substantiated by Soft Gel Technologies and Optio Health Products after an inquiry from the National Advertising Division. The Council for Better Business Bureaus group Oct. 6 says as part of an ongoing initiative with the Council for Responsible Nutrition, it examined Clarinol claims including: "Assists in reducing body fat and maintaining lean muscle tissue for healthy body composition" and "the clinical results show enhanced fat burning, lean muscle retention and promotion of optimal" body mass index. The watchdog group examined clinical studies as well as one study on the actual Clarinol conjugated linoleic acid product and "determined that the studies followed sound methodologies and produced statistically significant results demonstrating a reduction in body fat mass, BMI, waist, waist-to-hip ratio and fat mass around the legs and abdomen, as well as an increase in lean mass," NAD says
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.